Advertisement

Annals of Hematology

, Volume 95, Issue 8, pp 1383–1386 | Cite as

Sequential development of chronic myelogenous leukemia and primary myelofibrosis in a patient with history of large B-cell lymphoma treated with radiotherapy and chemotherapy: two myeloid neoplasms with distinct genotypic profiles suggestive of biclonality in a single individual

  • Bin Wu
  • Kimberly Ingersoll
  • Catherine Rehder
  • Siby Sebastian
  • Endi WangEmail author
Letter to the Editor

Dear Editor,

Hematopoietic neoplasms that develop after exposure to cytotoxic agents or therapeutic radiation primarily include myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), and acute myeloid leukemia (AML) [1]. Although much less frequently encountered, therapy-related B-lymphoblastic leukemia has also been reported in the literature [2]. Myeloproliferative neoplasm (MPN) arising as a therapy-related malignancy is exceedingly rare [1], and its pathogenesis has not been well characterized, particularly in relation to chemotherapeutic agents. Here, we report a case with the sequential development of biclonal MPNs; the patient initially developed chronic myelogenous leukemia (CML) and subsequently developed primary myelofibrosis (PMF) following the treatment for diffuse large B-cell lymphoma (DLBCL).

48-year-old Caucasian male was diagnosed with DLBCL in a left epitrochlear lymph node and was initially stage IA. He received local radiotherapy and...

Keywords

Chronic Myelogenous Leukemia Nilotinib Polycythemia Vera Ruxolitinib Jak2 V617F Mutation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We thank Steven Conlon in the Department of Pathology at Duke University Medical Center for the technical assistance of photo images and figure illustration.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Financial disclosure

None reported.

References

  1. 1.
    Zhang L, Wang SA (2014) A focused review of hematopoietic neoplasms occurring in the therapy-related setting. Int J Clin Exp Pathol 7:3512–3523PubMedPubMedCentralGoogle Scholar
  2. 2.
    Chen W, Wang E, Lu Y, Gaal KK, Huang Q (2010) Therapy-related acute lymphoblastic leukemia without 11q23 abnormality: report of six cases and a literature review. Am J Clin Pathol 133:75–82CrossRefPubMedGoogle Scholar
  3. 3.
    Cambier N, Renneville A, Cazaentre T et al (2008) JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 22:1454–1455CrossRefPubMedGoogle Scholar
  4. 4.
    Aguiar RC (1998) Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma 29:17–26CrossRefPubMedGoogle Scholar
  5. 5.
    Zahra K, Ben Fredj W, Ben Youssef Y et al (2012) Chronic myeloid leukemia as a secondary malignancy after lymphoma in a child. A case report and review of the literature. Onkologie 35:690–693CrossRefPubMedGoogle Scholar
  6. 6.
    Demiriz IS, Tekgunduz E, Bozdag SC, Altuntas F (2014) Chronic myeloid leukemia as a secondary malignancy following treatment of diffuse large B-cell lymphoma. Turk J Haematol 31:92–94CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Xu XH, Huang LS, Yang J et al (2013) Chronic myeloid leukemia arising from acute myeloid leukemia: response to imatinib mesylate with favorable outcome. Leuk Lymphoma 54:195–197CrossRefPubMedGoogle Scholar
  8. 8.
    Lee HY, Lee KH, Hyun MS, Kim MK, Koh SA, Cho HS (2014) Chronic myeloid leukemia as a secondary malignancy after diffuse large B-cell lymphoma. Korean J Intern Med 29:250–252CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Menon NM, Katsanis E, Khalpey Z, Whitlow P (2015) Pediatric secondary chronic myeloid leukemia following cardiac transplantation for anthracycline-induced cardiomyopathy. Pediatr Blood Cancer 62:166–168CrossRefPubMedGoogle Scholar
  10. 10.
    Malfuson JV, Konopacki J, Fagot T et al (2011) Therapy-related myeloproliferative neoplasm with ETV6-PDGFRB rearrangement following treatment of acute promyelocytic leukemia. Ann Hematol 90:1477–1479CrossRefPubMedGoogle Scholar
  11. 11.
    Jabbour E, Kantarjian HM, Abruzzo LV et al (2007) Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110:2991–2995CrossRefPubMedGoogle Scholar
  12. 12.
    Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J (2006) Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108:2811–2813CrossRefPubMedGoogle Scholar
  13. 13.
    Ramanarayanan J, Dunford LM, Baer MR, Sait SN, Lawrence W, McCarthy PL (2006) Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients. Leuk Res 30:701–705CrossRefPubMedGoogle Scholar
  14. 14.
    Waldman D, Weintraub M, Freeman A, Neumann Y, Rechavi G, Toren A (2004) Favorable early response of secondary chronic myeloid leukemia to imatinib. Am J Hematol 75:217–219CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Bin Wu
    • 1
    • 2
  • Kimberly Ingersoll
    • 2
  • Catherine Rehder
    • 2
  • Siby Sebastian
    • 2
  • Endi Wang
    • 2
    • 3
    Email author
  1. 1.Division of Hematology, Department of MedicineShengjing Hospital affiliated with China Medical UniversityShenyangPeople’s Republic of China
  2. 2.Department of PathologyDuke University Medical CenterDurhamUSA
  3. 3.Department of PathologyDurhamUSA

Personalised recommendations